Helix BioPharma Corp. Closes Private Placement

    NEXT STORY
    Novartis’ phase III QUARTZ study of new investigational inhaled combination treatment QMF149 meets primary and key secondary endpoints in patients with inadequately controlled asthma
    PREV STORY
    Five Reasons Why Your Content Strategy is Failing
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Cyclacel Announces Reverse Stock Split

    author_avatar
    NASDAQ Market News

    Amendment to Sections 5 and 9(1) of the Articles of Association of Orion Corporation entered in the Trade Register

    ORION CORPORATION         STOCK EXCHANGE RELEASE 6 APRIL 2017 at 9.00 EET                      Amendment to Sections ...

    author_avatar
    NASDAQ Market News

    Active Pharmaceutical Ingredients Market is projected to reach a value of US$ 257,455.6 by 2026 – TMR

    Active Pharmaceutical Ingredients (API) Market: Increase in Government Prioritization for Biomedical Innovation Globally to ...

    author_avatar
    NASDAQ Market News